A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review

References

• Kashyap MK, Kumar A, Emelianenko N, et al. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers. 2005;10(4):258–294.
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–1939.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–3590.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134.
   PubMed Web of Science ®Google Scholar
• Houk BE, Bello CL, Kang D, et al. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15:2497–2506.
   PubMed Web of Science ®Google Scholar
• Suttle AB, Ball HA, Molimard M, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111(10):1909–1916.
   PubMed Web of Science ®Google Scholar
• Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011;13(2):103–111.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Pal SK, McDermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014;25(8):1603–1608.
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32(14):1412–1418.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722–731.
   PubMed Web of Science ®Google Scholar
• Garcia-Donas J, Rodriguez-Moreno JF, Romero-Laorden N, et al. Renal carcinoma pharmacogenomics and predictors of response: steps toward treatment individualization. Urol Oncol. 2015;33(4):179–186.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Antona C, Taron M. Pharmacogenomic biomarkers for personalized cancer treatment. J Intern Med. 2015;277(2):201–217.
   PubMed Web of Science ®Google Scholar
• Erdem L, Giovannetti E, Leon LG, et al. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr Top Med Chem. 2012;12(15):1649–1659.
   PubMed Web of Science ®Google Scholar
• Funakoshi T, Lee CH, Hsieh JJ. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat Rev. 2014;40(4):533–547.
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647. doi:10.1136/bmj.g7647.
   PubMed Web of Science ®Google Scholar
• International prospective register of systematic reviews [Internet]. [cited 2015 Nov 16]. Available from: www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015016509#.VR5WlE39laQ.
   Google Scholar
• Janssens A, Deverka P. Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing. Clin Pharmacol Ther. 2014;96(6):652–654.
   PubMed Web of Science ®Google Scholar
• Gillis N, Innocenti F. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. Clin Pharmacol Ther. 2014;96(6):655–657.
   PubMed Web of Science ®Google Scholar
• Van Erp N, Eechoute K, van der Veldt A, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol. 2009;27(26):4406–4412.
   PubMed Web of Science ®Google Scholar
• Garcia-Donas J, Esteban E, Leandro-García L, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011;12(12):1143–1150.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Lambrechts D, Van Brussel T, et al. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol. 2014;53(10):1413–1422.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Terada T, Kamba T, et al. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol. 2010;21(6):1382–1383.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Fukudo M, Terada T, et al. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. Drug Metab Pharmacokinet. 2012;27(6):631–639.
   PubMed Web of Science ®Google Scholar
• Miura Y, Imamura C, Fukunaga K, et al. Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype. BMC Cancer. 2014;14:964.
   PubMed Web of Science ®Google Scholar
• Eechoute K, van der Veldt A, Oosting S, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther. 2012;92(4):503–510.
   PubMed Web of Science ®Google Scholar
• Kim J, Vaziri S, Rini B, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer. 2012;118(7):1946–1954.
   PubMed Web of Science ®Google Scholar
• Kim H, Park H, Kwon W, et al. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol. 2013;72(4):825–835.
   PubMed Web of Science ®Google Scholar
• Takayoshi K, Sagara K, Uchino K, et al. A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine. BMC Cancer. 2015;15(1):426.
   PubMed Web of Science ®Google Scholar
• Teo Y, Wee H, Chue X, et al. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. Pharmacogenomics J. 2016;16(1):47–53.
   PubMed Web of Science ®Google Scholar
• Diekstra M, Swen J, Boven E, et al. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol. 2015;68:621–629.
   PubMed Web of Science ®Google Scholar
• Van der Veldt A, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res. 2011;17(3):620–629.
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Bianconi M, Faloppi L, et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer. 2013;108(5):1126–1132.
   PubMed Web of Science ®Google Scholar
• Motzer R, Hutson T, Hudes G, et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014;74(4):739–750.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Karadimou A, Lambrechts D, et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer. 2013;108(4):887–900.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Karadimou A, Lambrechts D, et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis. Acta Oncol. 2014;53(1):103–112.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Fukudo M, Fukuda T, et al. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. Ther Drug Monit. 2014;36(3):310–316.
   PubMed Web of Science ®Google Scholar
• Diekstra MH, Klümpen HJ, Lolkema MP, et al. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Ther. 2014;96(1):81–89.
   PubMed Web of Science ®Google Scholar
• Xu CF, Reck B, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphism. Br J Cancer. 2010;102(9):1371–1377.
   PubMed Web of Science ®Google Scholar
• Xu CF, Reck B, Goodman V, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol. 2011;54(6):1237–1243.
   PubMed Web of Science ®Google Scholar
• Xu CF, Bing N, Ball H, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol. 2011;29(18):2557–2564.
   PubMed Web of Science ®Google Scholar
• Motzer R, Johnson T, Choueiri T, et al. Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Ann Oncol. 2013;24(11):2927–2928.
   PubMed Web of Science ®Google Scholar
• Xu CF, Johnson T, Garcia-Donas J, et al. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. Br J Cancer. 2015;112(7):1190–1198.
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Narita S, Inoue T, et al. Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. Anticancer Drugs. 2013;24(3):310–314.
   PubMed Web of Science ®Google Scholar
• Escudier B, Rini B, Motzer R, et al. Genotype correlations with blood pressure and efficacy from a randomized phase III trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015;13(4):328–337.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Mosquera JM, Hirsch MS. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer. 2009;7(3):E93–E94.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Job S, Becht E, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res. 2015;21(6):1329–1339.
   PubMed Web of Science ®Google Scholar
• Paule B, Bastien L, Deslandes E, et al. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. Plos One. 2010;5(5):e10715.
   PubMed Web of Science ®Google Scholar
• Gruenwald V, Beutel G, Schuch-Jantsch S, et al. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer. 2010;10:695.
   PubMed Web of Science ®Google Scholar
• D’Alterio C, Portella L, Ottaiano A, et al. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. Curr Cancer Drug Targets. 2012;12(6):693–702.
   PubMed Web of Science ®Google Scholar
• Garcia-Donas J, Leandro-García L, González Del Alba A, et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. 2013;24(9):2409–2414.
   PubMed Web of Science ®Google Scholar
• Minardi D, Lucarini G, Santoni M, et al. VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. Anticancer Res. 2013;33(11):5017–5022.
   PubMed Web of Science ®Google Scholar
• Sato M, Nakai Y, Nakata W, et al. EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome. Plos One. 2013;8(9):e74313.
   PubMed Web of Science ®Google Scholar
• Del Puerto-Nevado L, Rojo F, Zazo S, et al. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy. Br J Cancer. 2014;110(11):2700–2707.
   PubMed Web of Science ®Google Scholar
• Gambini D, Locatelli E, Gianelli U. Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor? Anticancer Res. 2014;34(12):7361–6365.
   PubMed Web of Science ®Google Scholar
• Mikami S, Mizuno R, Kosaka T, et al. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Int J Cancer. 2015;136(7):1504–1514.
   PubMed Web of Science ®Google Scholar
• Dornbusch J, Zacharis A, Meinhardt M, et al. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. Plos One. 2013;8(9):e76386.
   PubMed Web of Science ®Google Scholar
• Gámez-Pozo A, Antón-Aparicio L, Bayona C, et al. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia. 2012;14(12):1144–1152.
   PubMed Web of Science ®Google Scholar
• Berkers J, Govaere O, Wolter P, et al. A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance. J Urol. 2013;189(5):1930–1938.
   PubMed Web of Science ®Google Scholar
• Prior C, Perez-Gracia J, Garcia-Donas J, et al. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. Plos One. 2014;9(1):e86263.
   PubMed Web of Science ®Google Scholar
• Choueiri T, Fay A, Gagnon R, et al. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2013;19(18):5218–5226.
   PubMed Web of Science ®Google Scholar
• Peña C, Lathia C, Shan M, et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res. 2010;16(19):4853–4863.
   PubMed Web of Science ®Google Scholar
• Feng G, Ye X, Fang F, et al. Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. Dis Markers. 2013;34(2):105–111.
   PubMed Web of Science ®Google Scholar
• Aziz S, Sznol J, Albiges L, et al. Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell Int. 2014;14(1):4.
   PubMed Web of Science ®Google Scholar
• Zheng B, Zhu H, Gu D, et al. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib. Biochem Biophys Res Commun. 2015;459(2):234–239.
   PubMed Web of Science ®Google Scholar
• Doberstein K, Wieland A, Lee S, et al. L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis. 2011;32(3):262–270.
   PubMed Web of Science ®Google Scholar
• Furuya N, Kamai T, Shirataki H, et al. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma. Cancer Immunol Immunother. 2011;60(6):793–808.
   PubMed Web of Science ®Google Scholar
• Sharpe K, Stewart G, Mackay A, et al. The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res. 2013;19(24):6924–6934.
   PubMed Web of Science ®Google Scholar
• Yamada D, Matsushita H, Azuma T, et al. Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy. Mol Clin Oncol. 2014;2(6):1023–1027.
   PubMedGoogle Scholar
• Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13(8):827–837.
   PubMed Web of Science ®Google Scholar
• Peters I, Dubrowinskaja N, Abbas M, et al. DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies. Plos One. 2014;9(3):e91440.
   PubMed Web of Science ®Google Scholar
• Dubrowinskaja N, Gebauer K, Peters I, et al. Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response. Cancer Med. 2014;3(2):300–309.
   PubMed Web of Science ®Google Scholar
• Choudhury Y, Wei X, Chu Y, et al. A multigene assay identifying distinct prognostic subtypes of clear cell renal cell carcinoma with differential response to tyrosine kinase inhibition. Eur Urol. 2015;67(1):17–20.
   PubMed Web of Science ®Google Scholar
• Maitland M, Ratain M, Cox N. Interpreting P values in pharmacogenetic studies: a call for process and perspective. J Clin Oncol. 2007;25(29):4513–4515.
   PubMed Web of Science ®Google Scholar
• Van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35(8):692–706.
   PubMed Web of Science ®Google Scholar
• Diekstra M, Liu X, Swen J, et al. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2015;71(12):1477–1484.
   PubMed Web of Science ®Google Scholar
• Voora D. Building the evidentiary framework for pharmacogenetic testing: is it time to move beyond randomized controlled trials? Personalized Medicine. 2013;10(1):1–3.
   Web of Science ®Google Scholar
• Hayes D, Bast R, Desch C, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88(20):1456–1466.
   PubMed Web of Science ®Google Scholar
• Simon R, Paik S, Hayes D. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446–1452.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2):209–217.
   PubMed Web of Science ®Google Scholar
• The Dutch Pharmacogenetics Working Group [Internet]. [cited 2015 Nov 23]. Available from: https://www.pharmgkb.org/page/dpwg.
   Google Scholar
• Liu X, Hoang A, Zhou L, et al. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res. 2015;3(9):1017–1029.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Eng J Med. 2015;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• The Targeted Agent and Profiling Utilization Registry (TAPUR) study [Internet]. [cited 2015 Nov 23]. Available from: http://www.asco.org/practice-research/targeted-agent-and-profiling-utilization-registry-study.
   Google Scholar
• NCI trial on Molecular Analysis for Therapy Choice (NCI-MATCH) [Internet]. [cited 2015 Nov 23]. Available from: http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match.
   Google Scholar